Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (PYXS) is a clinical-stage biopharmaceutical company pioneering antibody-drug conjugates (ADCs) targeting components of the tumor microenvironment to address challenging cancers. This page provides investors and researchers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access timely updates on PYX-201 progress, partnership agreements, and regulatory milestones. Our curated collection includes earnings reports, preclinical data disclosures, and management commentary – all essential for evaluating the company’s position in oncology innovation.
Key content categories include ADC platform advancements, clinical trial phase transitions, and scientific collaborations. Users will find verified information on therapeutic mechanisms targeting extracellular matrix proteins like EDB+FN, a focus area distinguishing Pyxis in immuno-oncology.
Bookmark this page for streamlined access to material events affecting Pyxis Oncology’s trajectory. Check regularly for new developments in their pipeline programs and evidence-based analysis of therapeutic candidates.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
